Physician profile
Jonathan H Moore
NPI 1588762223
$1,467.67
in general payments reported to CMS, 2019-2025
21 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $59.28 · 2021: $81.46 · 2022: $389 · 2023: $181 · 2024: $327 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.16 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $186.79 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $159.28 | 2022-2025 | Clareon, Argos |
| Aerie Pharmaceuticals, INC. | $102.01 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $90.20 | 2019-2023 | Cequa |
| Allergan, INC. | $80.32 | 2019-2022 | |
| Glaukos Corporation | $72.38 | 2024 | Ce-Marked Kxla System |
| Alexion Pharmaceuticals, INC. | $68.76 | 2022 | |
| Mallinckrodt Hospital Products INC. | $63.54 | 2022-2025 | Acthar |
| Oyster Point Pharma, INC. | $60.20 | 2022-2025 | Tyrvaya |
| Shire North American Group INC | $43.42 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.13 | 2023 | |
| Rayner Intraocular Lenses Limited | $24.06 | 2025 | Omidria |
| Biotissue Holdings INC. | $22.89 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.51 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $21.26 | 2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Ocular Therapeutix, INC. | $20.52 | 2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $19.17 | 2024 | Xdemvy |
| Sight Sciences, INC. | $15.87 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Astellas Pharma US INC | $15.48 | 2025 | Izervay |
| Carl Zeiss Meditec, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.